Skip to main content
Normal View

Medicinal Products

Dáil Éireann Debate, Tuesday - 22 September 2020

Tuesday, 22 September 2020

Questions (707)

Rose Conway-Walsh

Question:

707. Deputy Rose Conway-Walsh asked the Minister for Health the availability of fluphenazine decanoate as a treatment for schizophrenia; and if he will make a statement on the matter. [24787/20]

View answer

Written answers

The Health Products Regulatory Authority (HPRA), the competent authority for medicines in Ireland, has advised that there are no products authorised in Ireland with the active ingredient fluphenazine decanoate. All national products previously authorised with fluphenazine decanoate have been withdrawn, and there are no centrally authorised products with this active ingredient.

The HPRA are aware, through the exempt medicines notification scheme, that fluphenazine products from other markets have been imported into Ireland for use by Irish patients. Patients who require fluphenazine should contact their doctor and local pharmacy about obtaining the medicine through this route.

If a patient has any concerns regarding their treatment with this or any other medication, they should discuss this directly with their doctor or pharmacist.

Top
Share